Persistent neurocognitive decline in a clinic sample of hepatitis C virus-infected persons receiving interferon and ribavirin treatment

Journal of NeuroVirology

Volumn 20, Issue 6, 2014, Pages 561-570

  Cattie, Jordan E ^a   Letendre, Scott L ^b   Woods, Steven Paul ^a   Barakat, Fatma ^b   Perry, William ^a   Cherner, Mariana ^a   Umlauf, Anya ^a   Franklin, Donald ^a   Heaton, Robert K ^a   Hassanein, Tarek ^b   Grant, Igor ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Antiviral treatment; Cognitive dysfunction impairment; Depressive symptoms; Neuropsychological effects; Side effects (treatment)

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; DEPRESSION; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; LIVER DISEASE; MALE; MIDDLE AGED; NEUROCOGNITIVE DECLINE; NEUROPSYCHOLOGICAL TEST; PREDICTION; VIRAL CLEARANCE; VIRUS LOAD; AFFECT; COGNITION; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; GENETICS; GENOTYPE; GROWTH, DEVELOPMENT AND AGING; HEPACIVIRUS; HEPATITIS C, CHRONIC; LONGITUDINAL STUDY; PATHOPHYSIOLOGY; PSYCHOLOGIC TEST; VIROLOGY;

HEPATITIS C VIRUS;

ADULT; AFFECT; ANTIVIRAL AGENTS; COGNITION; DEPRESSION; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PSYCHOLOGICAL TESTS; RECOMBINANT PROTEINS; RIBAVIRIN; VIRAL LOAD;

EID: 84916884440     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-014-0265-3     Document Type: Article

References (38)

1. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. Author, Washington, DC.
2. Asnis GM, De La Garza R (2006) Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 40:322–335
3. Beck AT (1987) The beck depression inventory. Psychological Corporation, San Antonio
4. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, Heaton RK (2004) Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 26:307–319
5. Córdoba J, Flavià M, Jacas C, Sauleda S, Esteban JI, Vargas V, Esteban R, Guardia J (2003) Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol 39:231–238
6. Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, McCutchan JA, Heaton RK, Ellis RJ (2009) Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 73:342–348. doi:10.1212/WNL.0b013e3181ab2b3b
7. de Knegt RJ, Bezemer G, Van Gool AR, Drenth JP, Hansen BE, Droogleever Fortuyn HA, Weegink CJ, Hengeveld MW, Janssen HL (2011) Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon‐alfa‐2a and ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 34:1306–1317. doi:10.1111/j.1365-2036.2011.04867
8. Dusheiko G (1997) Side effects of alpha interferon in chronic hepatitis C. Hepatology 26:S112S–S121S
9. Fontana RJ (2000) Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis 18:107–116
10. Forton D, Karayiannis P (2006) Established and emerging therapies for the treatment of viral hepatitis. Dig Dis 24:160–173
11. Forton DM, Allsop JM, Cox IJ, Hamilton G, Wesnes K, Thomas HC, Taylor-Robinson SD (2005) A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. AIDS 19:S53–S63
12. Gane E, Stedman C, Hyland R, Sorensen R, Symonds W, Hindes R, Berrey M (2012) Once daily GS-7977 plus ribavirin in HCV genotypes 1–3: the ELECTRON trial. Hepatology 56:306A–307A
13. Heaton RK, Kirson D, Velin RA, Grant I, The HNRC Group (1994) The utility of clinical ratings for detecting cognitive change in HIV infection. In: Grant I, Martin A (eds) Neuropsychology of HIV infection. Oxford University Press, New York, pp 188–206
14. Hilsabeck RC, Perry W, Hassanein TI (2002) Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 35:440–446
15. Hilsabeck RC, Hassanein TI, Ziegler EA, Carlson MD, Perry W (2005) Effect of interferon-[alpha] on cognitive functioning in patients with chronic hepatitis C. J Int Neuropsychol Soc 11:16–22
16. Kraus MR, Schäfer A, Faller H, Csef H, Scheurlen M (2002) Paroxetine for the treatment of interferon‐α‐induced depression in chronic hepatitis C. Aliment Pharmacol Ther 16:1091–1099
17. Laskus T, Radkowski M, Adair DM, Wilkinson J, Scheck AC, Rakela J (2005) Emerging evidence of hepatitis C virus neuroinvasion. AIDS 19:S140–S144
18. McAndrews MP, Farcnik K, Carlen P, Damyanovich A, Mrkonjic M, Jones S, Heathcote EJ (2005) Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 41:801–808
19. McNutt MD, Liu S, Manatunga A, Royster EB, Raison CL, Woolwine BJ, Demetrashvili MF, Miller AH, Musselman DL (2012) Neurobehavioral effects of Interferon-alpha in patients with Hepatitis-C: symptom dimensions and responsiveness to paroxetine. Neuropsychopharmacology 37:1444–1454. doi:10.1038/npp.2011.330
20. Murray J, Fishman SL, Ryan E, Eng FJ, Walewski JL, Branch AD, Morgello S (2008) Clinicopathologic correlates of hepatitis C virus in brain: a pilot study. J Neurovirol 14:17–27. doi:10.1080/13550280701708427
21. Neri S, Bertino G, Petralia A, Giancarl C, Rizzotto A, Calvagno GS et al (2010) A Multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated Interferon and Ribavirin. J Clin Gastroenterol 44:210–217. doi:10.1097/MCG.0b013e3181d88af5
22. Pattullo V, McAndrews MP, Damyanovich A, Heathcote EJ (2011) Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: validation from therapeutic outcomes. Liver Int 31:1028–1038. doi:10.1111/j.1478-3231.2011.02549
23. Raison CL, Borisov AS, Majer M, Drake DF, Pagnoni G, Woolwine BJ, Vogt GL, Massung B, Miller AH (2009) Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry 65:296–303. doi:10.1016/j.biopsych.2008.08.010
24. Reichenberg A, Gorman JM, Dieterich DT (2005) Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS 19:S174–S178
25. Russo MA, Fried MW (2003) Side effects of antiviral therapy for hepatitis C. Gastroenterology 124:1711–1719
26. Schaefer M, Engelbrechta MA, Gut O, Fiebich BL, Bauer J, Schmidt F, Grunze H, Lieb K (2002) Interferon alpha (IFNα) and psychiatric syndromes: a review. Prog Neuro-Psychopharmacol Biol Psychiatry 26:731–746
27. Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, Foster GR, Kautz A, Forton D, Pariante CM (2012) Hepatitis C infection, antiviral treatment and mental health: a European Expert Consensus Statement. J Hepatol 57:1379–1390. doi:10.1016/j.jhep.2012.07.037
28. Schmidt F, Janssen G, Martin G, Lorenzs R, Loeschkes K, Soyka M, Folwaczny C, Schaefer M (2009) Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C. Aliment Pharmacol Ther 30:1049–1059. doi:10.1111/j.1365-2036.2009.04123
29. Sene D, Limal N, Cacoub P (2004) Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis 19:357–381
30. Senzolo M, Schiff S, D’Aloiso CM, Crivellin C, Cholongitas E, Burra P, Montagnese S (2011) Neuropsychological alterations in hepatitis C infection: the role of inflammation. World J Gastroenterol 17:3369. doi:10.3748/wjg.v17.i29.3369
31. Thein HH, Maruff P, Krahn MD, Kaldor JM, Koorey DJ, Brew BJ, Dore GJ (2007) Improved cognitive function as a consequence of hepatitis C virus treatment. HIV Med 8:520–528
32. Valentine AD, Meyers CA (2005) Neurobehavioral effects of interferon therapy. Curr Psychiatr Rep 7:391–395
33. Vargas HE, Laskus T, Radkowski M, Wilkinson J, Balan V, Douglas DD, Harrison ME, Mulligan DC, Olden K, Adair D, Rakela J (2002) Detection of hepatitis C virus sequences in brain tissue obtained in recurrent hepatitis C after liver transplantation. Liver Transpl 8:1014–1019
34. Weissenborn K, Krause J, Bokemeyer M, Hecker H, Schüler A, Ennen JC, Ahl B, Manns MP, Boker KW (2004) Hepatitis C virus infection affects the brain—evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 41:845–851
35. Wilkinson GS, Robertson GJ (2006) Wide range achievement test-4 (WRAT-4) Lutz. Psychological Assessment Resources Inc, FL
36. Wilkinson J, Radkowski M, Laskus T (2009) Hepatitis C virus neuroinvasion: identification of infected cells. J Virol 83:1312–1319. doi:10.1128/JVI.01890-08
37. World Health Organization (1998) Composite international diagnostic interview (CIDI, version 2.1). World Health Organization, Geneva
38. Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Mo H, Aterburn S, Knox S, Oldach D, McHutchison JG, Manns MP, Foster GR (2012) The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 55:749–758